A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.

Dihydroergotamine

Level of risk reviewed on 07/05/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk probable, is now set to Low Risk probable.

Ipilimumab

Level of risk reviewed on 03/05/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk probable, is now set to Low Risk probable.

Ergotamine Tartrate

Level of risk reviewed on 01/05/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk probable, is now set to Low Risk probable.

Metamizole

Level of risk reviewed on 08/04/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk probable, is now set to High Risk probable.

Cetuximab

Level of risk reviewed on 03/04/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk probable, is now set to Low Risk probable.

Technetium 99m DiMercaptoSuccinic Acid (DMSA)

Level of risk reviewed on 30/03/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk probable, is now set to Very Low Risk.

Technetium 99m Exametazime (HMPAO)

Level of risk reviewed on 30/03/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk probable, is now set to Very Low Risk.

Technetium 99m Medronate (MDP)

Level of risk reviewed on 30/03/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk probable, is now set to Very Low Risk.

Levosulpiride

Level of risk reviewed on 26/02/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk probable.

Bearberry

Level of risk reviewed on 25/02/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk probable, is now set to Low Risk probable.

Oxytocin

Level of risk reviewed on 22/02/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk probable.